Arena Capital Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Arena Capital Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,717	Closed	-$57.7K	–	147
2022 Q4	$57.7K	Hold	5,717	–	–	0.03%	80
2022 Q3	$57K	Hold	5,717	–	–	0.02%	127
2022 Q2	$56K	Sell	5,717 -98,025	-94%	-$959K	0.01%	153
2022 Q1	$1.01M	Sell	103,742 -197,157	-66%	-$1.92M	0.15%	121
2021 Q4	$2.92M	Hold	300,899	–	–	0.27%	123
2021 Q3	$2.93M	Buy	300,899 +225,899	+301%	+$2.18M	0.23%	134
2021 Q2	$731K	Buy	+75,000	New	+$737K	0.06%	262

Arena Capital Advisors's EBAC Position: Q1 2023 in Review

Arena Capital Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 5,717 shares — an estimated $57.7K sold.

Arena Capital Advisors first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $2.93M in Q3 2021. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Arena Capital Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Arena Capital Advisors sold 5,717 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $57.7K.
Arena Capital Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Arena Capital Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.93M in Q3 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Arena Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.